We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Provides New Guidelines for Cleaning Duodenoscopes

FDA Provides New Guidelines for Cleaning Duodenoscopes

October 2, 2015

Following the outbreak of infections related to a deadly superbug, the FDA has provided new guidelines to help healthcare facilities ensure their duodenoscopes are cleaned adequately.

Duodenoscopes gained intense media scrutiny after reports of antibiotic-resistant infections in Chicago, Pittsburgh, Seattle and Los Angeles. Earlier this year, the FDA revealed that between January 2013 and December 2014, it had received 75 reports involving about 135 patients suffering from carbapenem-resistant Enterobacteriaceae transmissions linked to these devices.

The FDA acknowledges that the duodenoscope’s unique design is useful for performing endoscopic retrograde cholangiopancreatography procedures. This utility has its drawbacks, however, as the device has small working parts, including a moveable elevator mechanism with tiny crevices. This elevator is particularly difficult to clean and disinfect properly, even if a healthcare professional adheres to a manufacturer’s instructions for use.

“Meticulous adherence to the manufacturer’s reprocessing instructions is labor-intensive and prone to human error,” according to the agency.

To combat the threat of infection transmission, the FDA is recommending facilities adopt the following supplemental measures: microbiological culturing; ethylene oxide sterilization; use of a liquid chemical sterilant processing system; and repeat high-level disinfection.

“We recognize that not all healthcare facilities can implement one or more of these measures, which require specific resources, training, and expertise,” the FDA said. While this may be the case, it is still critical that those professionals in charge of reprocessing the devices have instructions for use at hand and remain proficient in performing all reprocessing steps.

In addition to the supplemental measures, the agency is urging healthcare facilities to adopt the following best practices:

  • Meticulously clean the elevator mechanism and recesses surrounding it by hand;
  • Implement a comprehensive quality control program for reprocessing duodenoscopes;
  • Review reprocessing recommendations from a consensus document from the American Society for Gastrointestinal Endoscopy and the Society for Healthcare Epidemiology of America.

The FDA notes that it is monitoring the situation and evaluating information from the healthcare community, adverse events reports and other sources. It also is partnering with The Joint Commission, the nation’s largest hospital accreditation body, and the Centers for Medicare & Medicaid Services to bolster hospitals’ adherence to duodenoscope cleaning instructions. In addition, the agency says it is working with industry as it modifies and validates instructions for cleaning duodenoscopes.

Whether you need to convince the FDA to accept a predicate device in a simple 510(k) filing, make design changes or implement UDI across a family of high-risk implantable devices, there’s one thing all regulatory professionals need — the most up-to-date, latest FDA regulations available. Get out bestselling Guide to FDA Medical Device Regulations today!

Medical Devices Quality Postmarket Safety

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing